Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kailera Therapeutics, Inc. - Common stock (NQ:KLRA)

12.17 -0.63 (-4.92%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kailera Therapeutics, Inc. - Common stock

News headline image
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗
Could this be what Novo needs to turn things around? 
Via The Motley Fool
Topics Initial Public Offering
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool
News headline image
2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗
Don't wait until clinical milestones send their share prices soaring. 
Via The Motley Fool
News headline image
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant ↗
Could this be the secret to Pfizer's rebound strategy? 
Via The Motley Fool
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗
It's important to consider your comfort with risk before diving in. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗
There's a new challenger to the more established players in the weight-loss drug space. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million ↗
Kailera Therapeutics, a clinical-stage biotech focused on obesity treatments, just reported a notable insider buy in recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.